{"product_id":"isrg-marketing-mix","title":"Intuitive Surgical, Inc. (ISRG): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made late-2025 Marketing Mix Analysis gives you a practical, research-based view of Intuitive Surgical, Inc. Business across product, place, promotion, and price, showing how robotic surgery systems, biopsy tools, instruments, accessories, and service contracts support recurring procedure-based revenue, global hospital and surgical-center sales, U.S., Europe, and Asia reach, China operations via a Fosun joint venture, Italy and Spain expansion, Germany and Bulgaria manufacturing, surgeon training for nearly \u003cstrong\u003e90,000\u003c\/strong\u003e surgeons, and a capital-plus-consumables pricing model tied to utilization volume.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eIntuitive Surgical’s product mix is built around capital equipment, recurring instruments and accessories, and service contracts. The business depends on an installed base of \u003cstrong\u003e8,606\u003c\/strong\u003e da Vinci systems worldwide at year-end 2023, because each procedure can generate repeat demand for consumables and support services.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduct mix structure\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct line\u003c\/th\u003e\n\u003cth\u003eRole in the mix\u003c\/th\u003e\n\u003cth\u003eReal-life product facts\u003c\/th\u003e\n\u003cth\u003eCommercial role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eda Vinci 5\u003c\/td\u003e\n\u003ctd\u003eFlagship soft-tissue robotic surgery platform\u003c\/td\u003e\n\u003ctd\u003e4-arm system; FDA cleared in 2024; Force Feedback\u003c\/td\u003e\n\u003ctd\u003eNew capital system and replacement-cycle driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eda Vinci Xi\u003c\/td\u003e\n\u003ctd\u003eInstalled-base soft-tissue system\u003c\/td\u003e\n\u003ctd\u003e4-arm multiport platform; broad procedure coverage\u003c\/td\u003e\n\u003ctd\u003eCore hospital platform tied to recurring instrument use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIon\u003c\/td\u003e\n\u003ctd\u003eEndoluminal biopsy system\u003c\/td\u003e\n\u003ctd\u003eRobotic bronchoscopy platform for peripheral lung biopsy\u003c\/td\u003e\n\u003ctd\u003eExpands the company beyond surgery into diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruments and accessories\u003c\/td\u003e\n\u003ctd\u003eRecurring product layer\u003c\/td\u003e\n\u003ctd\u003eProcedure-linked consumables and accessories\u003c\/td\u003e\n\u003ctd\u003eHigh-frequency revenue stream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contracts\u003c\/td\u003e\n\u003ctd\u003eRecurring support layer\u003c\/td\u003e\n\u003ctd\u003eMaintenance, uptime support, installation, and software support\u003c\/td\u003e\n\u003ctd\u003eRevenue attached to the installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCE-marked soft-tissue portfolio\u003c\/td\u003e\n\u003ctd\u003eEuropean product range\u003c\/td\u003e\n\u003ctd\u003eda Vinci Xi, da Vinci X, da Vinci SP\u003c\/td\u003e\n\u003ctd\u003eRegional product coverage across 3 platforms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eda Vinci 5 robotic surgery platform\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eda Vinci 5 is the newest major product in the portfolio. It is a 4-arm soft-tissue surgery system and the first new flagship platform after da Vinci Xi. Its importance is strategic: new system sales refresh the capital base, while the installed systems continue to generate recurring instrument and service demand. The product also strengthens Intuitive Surgical’s position in hospital purchasing decisions because system upgrades can influence operating room planning, surgeon workflow, and capital budgeting.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4-arm surgical platform\u003c\/li\u003e\n\u003cli\u003eFDA cleared in 2024\u003c\/li\u003e\n\u003cli\u003eBuilt for soft-tissue surgery\u003c\/li\u003e\n\u003cli\u003eSupports the capital replacement cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eda Vinci Xi installed-base system\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eda Vinci Xi remains the company’s installed-base workhorse. It is a 4-arm multiport system used across a broad set of soft-tissue procedures, which makes it central to utilization, procedure volume, and recurring product pull-through. The scale of the installed base matters because a larger installed base supports more instrument sales, more accessories, and more service contracts. With \u003cstrong\u003e8,606\u003c\/strong\u003e da Vinci systems installed worldwide at year-end 2023, the company has a large recurring product engine behind the platform business.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIon endoluminal biopsy system\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIon is a separate robotic platform for endoluminal biopsy, especially peripheral lung tissue sampling. It is not a soft-tissue surgery system, so it expands the company’s product set into pulmonary diagnostics. That matters because it gives Intuitive Surgical another clinical workflow, another customer use case, and another route into hospital and physician adoption. Ion also helps broaden the company’s exposure beyond operating-room surgery and into earlier diagnostic decision-making.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRobotic bronchoscopy platform\u003c\/li\u003e\n\u003cli\u003eUsed for peripheral lung biopsy\u003c\/li\u003e\n\u003cli\u003eDifferent workflow from abdominal or pelvic surgery\u003c\/li\u003e\n\u003cli\u003eExpands the addressable clinical use set\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstruments, accessories, and service contracts\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is the recurring core of the product mix. Instruments and accessories are used on a procedure basis, so they turn installed systems into repeat revenue. Service contracts add another recurring layer through maintenance, technical support, installation, and software support. This part of the mix matters because it makes revenue less dependent on one-time system placements. A hospital that already owns a da Vinci system can keep generating product demand with every procedure, which is why the installed base is so important to the business model.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRecurring product layer\u003c\/th\u003e\n\u003cth\u003eWhat it includes\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruments\u003c\/td\u003e\n\u003ctd\u003eProcedure-linked surgical tools\u003c\/td\u003e\n\u003ctd\u003eRepeat purchases tied to case volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories\u003c\/td\u003e\n\u003ctd\u003eSupporting components and consumables\u003c\/td\u003e\n\u003ctd\u003eRaises per-procedure revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contracts\u003c\/td\u003e\n\u003ctd\u003eMaintenance and support agreements\u003c\/td\u003e\n\u003ctd\u003eProtects uptime and extends system life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCE-marked soft-tissue robotic surgery portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn Europe, Intuitive Surgical’s CE-marked soft-tissue robotic surgery portfolio has centered on \u003cstrong\u003e3\u003c\/strong\u003e da Vinci platforms: da Vinci Xi, da Vinci X, and da Vinci SP. That gives the company a layered product lineup for different procedure types and hospital budgets. The product strategy matters because it lets the company sell into a broad range of hospitals while keeping the same recurring economics from instruments, accessories, and service.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eda Vinci Xi\u003c\/li\u003e\n\u003cli\u003eda Vinci X\u003c\/li\u003e\n\u003cli\u003eda Vinci SP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024 revenue: $8.35 billion\u003c\/strong\u003e. The company sells robotic surgery systems, instruments, accessories, and service through hospitals and surgical centers, and its footprint reaches \u003cstrong\u003eover 70\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal hospital and surgical-center sales\u003c\/strong\u003e depend on direct institutional selling, installed-base support, clinical training, and recurring instrument and service supply. That makes place an operating-room access issue, not a retail distribution issue, because availability depends on hospital buying teams, service coverage, and system placement at medical accounts.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlace element\u003c\/td\u003e\n\u003ctd\u003eReal-life footprint\u003c\/td\u003e\n\u003ctd\u003eNumeric data\u003c\/td\u003e\n\u003ctd\u003ePlace impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital and surgical-center sales\u003c\/td\u003e\n\u003ctd\u003eInstitutional distribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAccess through medical institutions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorldwide presence\u003c\/td\u003e\n\u003ctd\u003eCommercial reach across hospitals and surgical centers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOver 70\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eLocal availability across regions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003eFosun joint venture\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e joint venture\u003c\/td\u003e\n\u003ctd\u003eLocal market access and support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eItaly and Spain\u003c\/td\u003e\n\u003ctd\u003eDistribution expansion\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eBroader European coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany and Bulgaria\u003c\/td\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eRegional supply support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eUnited States, Europe, and Asia\u003c\/strong\u003e form the core commercial footprint. The place strategy is built around proximity to hospital purchasing teams, operating-room staff, and service organizations, which is why the company keeps local access in each major region instead of relying on a single export channel.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eChina operations via the Fosun joint venture\u003c\/strong\u003e give the company a local route into the market. That matters because China requires domestic commercial execution, local service support, and regulatory alignment, all of which are easier to manage through a joint venture structure than through cross-border sales alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eItaly and Spain distribution expansion\u003c\/strong\u003e shows continued European reach beyond the U.S. core. Adding country-level distribution coverage improves account access for hospitals and surgical centers, shortens delivery paths, and makes local service and training easier to coordinate.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGermany and Bulgaria manufacturing sites\u003c\/strong\u003e support European supply and availability. Manufacturing closer to end markets reduces dependence on a single country for production and helps keep systems, instruments, and service parts closer to hospital customers.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.35 billion\u003c\/strong\u003e revenue in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOver 70\u003c\/strong\u003e countries in the footprint\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e Fosun joint venture in China\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e European distribution expansion markets: Italy and Spain\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e manufacturing countries: Germany and Bulgaria\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003ePromotion is built around physician education, clinical proof, and procedure-volume data. The clearest public numbers are nearly \u003cstrong\u003e90,000\u003c\/strong\u003e surgeons trained worldwide, \u003cstrong\u003e2,683,000\u003c\/strong\u003e procedures in \u003cstrong\u003e2024\u003c\/strong\u003e, and FDA clearance of da Vinci \u003cstrong\u003e5\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSurgeon training and education programs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIntuitive Surgical, Inc. uses surgeon training as a core promotion tool because the buying decision sits with hospitals and surgeons, not patients. The company’s public training disclosure shows nearly \u003cstrong\u003e90,000\u003c\/strong\u003e surgeons trained worldwide. That scale matters because training lowers adoption friction, creates familiarity with the system, and supports future procedure volume. In a capital equipment business, training is part of the sales funnel and part of the utilization story after installation. The number also gives academic users a clean metric for measuring how promotion links to adoption.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003eReal-life number\u003c\/th\u003e\n\u003cth\u003eTiming\u003c\/th\u003e\n\u003cth\u003eBusiness use\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon training\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e90,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024 disclosure\u003c\/td\u003e\n\u003ctd\u003ePhysician education scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure volume\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,683,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUtilization message\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e versus \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAdoption signal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory proof point\u003c\/td\u003e\n\u003ctd\u003eda Vinci \u003cstrong\u003e5\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFDA clearance message\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCorporate Impact Report physician-training disclosure\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Corporate Impact Report turns surgeon training into a public credibility metric. A disclosure of nearly \u003cstrong\u003e90,000\u003c\/strong\u003e trained surgeons works like a promotion asset because it shows scale, reach, and repeat engagement with physicians. For academic writing, this is useful because it links a non-financial disclosure to commercial strategy. The message is simple: Intuitive Surgical, Inc. is not only selling systems; it is building a trained user base large enough to support ongoing procedure growth.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNearly \u003cstrong\u003e90,000\u003c\/strong\u003e surgeons trained worldwide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e Corporate Impact Report disclosure\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e public physician-training metric that supports commercial messaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory approvals as clinical proof points\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRegulatory clearance is part of promotion because it gives the product a clinical and legal milestone. da Vinci \u003cstrong\u003e5\u003c\/strong\u003e received FDA clearance in \u003cstrong\u003e2024\u003c\/strong\u003e. That date matters because it lets Intuitive Surgical, Inc. use a clear, verifiable proof point in surgeon and hospital conversations. A regulatory approval is not advertising copy; it is a formal threshold that supports product credibility. In promotion terms, it tells buyers that the system has passed a defined regulatory process before wider use.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eda Vinci \u003cstrong\u003e5\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFDA clearance in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e510(k) clearance pathway\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eProcedure-growth and utilization messaging\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProcedure volume is the strongest promotion signal because it shows real use, not just interest. Intuitive Surgical, Inc. reported \u003cstrong\u003e2,683,000\u003c\/strong\u003e da Vinci procedures in \u003cstrong\u003e2024\u003c\/strong\u003e, up \u003cstrong\u003e17%\u003c\/strong\u003e from \u003cstrong\u003e2023\u003c\/strong\u003e. On a \u003cstrong\u003e366\u003c\/strong\u003e-day year basis, that equals about \u003cstrong\u003e7,332\u003c\/strong\u003e procedures per day. This matters because higher utilization supports training programs, strengthens hospital ROI discussions, and gives sales teams a number they can point to in provider conversations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eExtra detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual procedures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,683,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-year growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e versus \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage procedures per day\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e7,332\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,683,000\u003c\/strong\u003e divided by \u003cstrong\u003e366\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eIntuitive Surgical, Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e of revenue and \u003cstrong\u003e2.2 million\u003c\/strong\u003e procedures in 2023 point to a pricing model built on a capital system sale plus recurring procedure-linked spending.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2023 revenue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2023 procedures\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue per procedure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eabout $3,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e divided by \u003cstrong\u003e2.2 million\u003c\/strong\u003e equals about \u003cstrong\u003e$3,200\u003c\/strong\u003e per procedure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$7.12 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2.2 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eabout $3,200\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602224345237,"sku":"isrg-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/isrg-marketing-mix.png?v=1740185878","url":"https:\/\/dcf-analysis.com\/products\/isrg-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}